News
Kamada gets Orphan Drug designation for AAT in Bronchiectasis
NESS ZIONA, Israel—Kamada, a biopharmaceutical company which develops, manufactures and markets specialty life-saving therapeutics, announces today that the company was granted an Orphan Drug Designation to its Aerosolized Alpha-1 Antitrypsin (AAT) product to treat Bronchiectasis.
Kamada’s aerosolized AAT product for treating Bronchiectasis, a lung disease that results in the distortion of one or more of the conducting bronchi or airways, is currently undergoing Phase II clinical trials.
According to David Tsur, CEO Kamada, “This significant recognition grants Kamada various benefits such as research fund support, tax incentives, reduced user fees and seven years of exclusive distribution rights, if the company’s product is first on the US market for this indication.”
